lisocabtagene maraleucel

AXP000016.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
CD19
Originator
Juno Therapeutics
Sponsor
Bristol Myers Squibb

Names

NameTypeSource
lisocabtagene maraleucelpreferred name, INNcurator, ncit
Breyanzibrandncit
JCAR017codencit
liso-celsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
replication-incompetent lentiviral vector; FMC63-derived anti-CD19 scFv, IgG4 hinge, CD28 transmembrane domain, 4-1BB costimulatory domain, CD3 zeta signalling domain; the cells also express a non-functional truncated EGFR (EGFRt)
Transgenes
anti-CD19 chimeric antigen receptor, truncated EGFR (EGFRt)
Route
ex vivo, intravenous
Carrier
autologous CD8+ and CD4+ T cells, activated and transduced separately and supplied as two components making one dose
Source
evidence

Cross-references

NCI Thesaurus
C125192
Wikidata
Q105605102
FDA UNII
7K2YOJ14X0

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2021-02-05approvedBreyanziAdults with large B-cell lymphoma after first-line chemoimmunotherapy failure or other listed criteria; relapsed or refractory CLL or SLL after two or more lines including a BTK and a BCL-2 inhibitor (accelerated approval); follicular lymphoma; mantle cell lymphoma; and marginal zone lymphoma. Not for primary CNS lymphomasource
PMDAJP2021-03-22approvedBreyanziRelapsed or refractory large B-cell lymphoma (diffuse large B-cell, primary mediastinal large B-cell, transformed indolent non-Hodgkin and high-grade B-cell lymphoma) and relapsed or refractory follicular lymphoma, in patients not previously given CD19-directed CAR T cellssource
EMAEU2022-04-04approvedBreyanziAdults with DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or grade 3B follicular lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy, or after two or more lines; and relapsed or refractory mantle cell lymphoma after at least two lines including a BTK inhibitorsource

Clinical trials (36)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingPhase 22026-12-012029-10-2020Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07725406Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaRecruitingPhase 12026-112028-08-0132Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM)
NCT07711483GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingPhase 22026-09-152028-09-1556B-cell Lymphomas; Large B-cell Lymphoma; Lymphoma; Relapsed/Refractory Large B-cell Lymphoma
NCT07777120Liso-Cel in Relapsed/Refractory Marginal Zone LymphomaActive not recruiting2026-03-242048-03-31300Marginal Zone Lymphoma
NCT07316010Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaRecruitingPhase 22026-03-172029-03-2150Large B-cell Lymphoma
NCT07052305NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell LymphomaRecruitingPhase 12026-03-122027-11-3024Large B-cell Lymphoma
NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyRecruitingPhase 32026-01-122029-12400Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B Cell Lymphoma Relapsed; Large B-cell Lymphoma; Lymphoma, B-Cell; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma Refractory/ Relapsed; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma
NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaSuspendedPhase 1/22025-12-272030-10-0433Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma; Recurrent High-Grade B-Cell Lymphoma; Recurrent Indolent B-Cell Non-Hodgkin Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory Grade 3b Follicular Lymphoma; Refractory High-Grade B-Cell Lymphoma; Refractory Indolent B-Cell Non-Hodgkin Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma
NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingPhase 22025-11-062028-01-0965Lymphoma
NCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingRecruiting2025-02-042044-08-31300Follicular Lymphoma
NCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruiting2025-02-042044-09-30300Mantle Cell Lymphoma (MCL)
NCT06788639A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruiting2025-02-042044-06-30300Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
NCT06550141Emapalumab Prevention of CAR-T Cell Associated ToxicitiesRecruitingPhase 22024-09-182027-08-0128Diffuse Large B Cell Lymphoma; Follicular Lymphoma; High-grade B-cell Lymphoma; Large B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma
NCT06313996A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaWithdrawnPhase 32024-03-292031-10-160Relapsed or Refractory Follicular Lymphoma
NCT06205290A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWithdrawnPhase 32024-01-162031-10-130Leukemia, Lymphocytic, Chronic, B-Cell
NCT06357754Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyRecruiting2023-10-062038-10-0650Chronic Lymphocytic Leukaemia; Multiple Myeloma; Non-Hodgkin Lymphoma
NCT05873712Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeRecruitingPhase 22023-07-282026-12-3124Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Transformed; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Non-Hodgkin Lymphoma; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
NCT05633615Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 22023-06-122030-06-30396Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Follic Lymph to Diff Large B-Cell Lymphoma; Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
NCT05672173Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationActive not recruitingPhase 22023-06-022027-08-249Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome
NCT05621096Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin LymphomaActive not recruitingPhase 12023-03-212025-01-2033DLBCL - Diffuse Large B Cell Lymphoma; Follicular Lymphoma; High-grade B-cell Lymphoma; Indolent B-Cell Non-Hodgkin Lymphoma; Mediastinal Large B-cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma
NCT05583149Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasActive not recruitingPhase 22023-03-012024-11-2328Aggressive B-cell NHL; C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma; C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma; DLBCL, Nos Genetic Subtypes; De Novo or Transformed Indolent B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); EBV-Positive DLBCL, Nos; Grade 3b Follicular Lymphoma; High-Grade B-Cell Lymphoma, Nos; Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL); Refractory Aggressive B-cell Lymphomas; Refractory B-Cell Non-Hodgkin Lymphoma; T Cell/Histiocyte-rich Large B-cell Lymphoma
NCT05359211NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell LymphomaCompletedPhase 12022-12-082025-09-0427Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory Grade 3b Follicular Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
NCT05075603Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 12021-07-292024-12-1817DLBCL Arising From Follicular Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma
NCT04855253Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/22021-06-092027-0930DLBCL; DLBCL Arising From Follicular Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma
NCT04245839A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active not recruitingPhase 22020-07-142031-09-30276Lymphoma, Non-Hodgkin
NCT03642626MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive not recruitingPhase 22018-12-182024-02-09150Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
NCT03744676A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedPhase 22018-11-292023-09-22104Immune System Disorder; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Neoplasms; Neoplasms by Histologic Type
NCT03575351A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin LymphomasCompletedPhase 32018-10-232023-10-23184Lymphoma, Non-Hodgkin
NCT03743246A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)TerminatedPhase 1/22018-10-172024-01-2621Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT03483103Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)CompletedPhase 22018-07-272021-09-2474Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, Nonhodgkin
NCT03484702Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin LymphomaCompletedPhase 22018-06-052023-12-15113Lymphoma, Non-Hodgkin
NCT03436771Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminated2018-02-192018-07-204Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Non Hodgkin Lymphoma
NCT03310619A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/22017-12-202023-02-1562Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin
NCT03331198Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Active not recruitingPhase 1/22017-11-272027-11-26320Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
NCT02631044Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedPhase 12016-01-062024-05-16387Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle-cell Lymphoma; Non-Hodgkin Lymphoma; Primary Mediastinal B-cell Lymphoma
NCT04400591Nonconforming Lisocabtagene Maraleucel Expanded Access ProtocolAvailableLymphoma, Large B-Cell, Diffuse

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41033998Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma.Internal medicine (Tokyo, Japan)2026name in abstract: lisocabtagene maraleucel
PMID 41692020Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.Lancet (London, England)2026cited by trial NCT04245839
PMID 41765136Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 41765468CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma in a nonagenarian patient.Journal of clinical and experimental hematopathology : JCEH2026name in abstract: lisocabtagene maraleucel
PMID 41836222Case Report: CAR-T therapy for relapsed diffuse large B-cell lymphoma in a patient with pre-existing Parkinson's disease-unfolding clinical challenges.Frontiers in oncology2026name in abstract: lisocabtagene maraleucel
PMID 41853416Successful Use of Chimeric Antigen Receptor T-cell (CAR-T) Therapy With Lisocabtagene Maraleucel in a Renal Transplant Recipient With Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).Cureus2026name in title: lisocabtagene maraleucel
PMID 42044466Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026cited by trial NCT03575351
PMID 42178058Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.Transplantation and cellular therapy2026name in abstract: liso-cel
PMID 42237652Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.Blood2026cited by trial NCT02631044
PMID 42285354Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 42462111Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.Blood2026cited by trial NCT04245839
PMID 42520199Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.Blood2026name in title: lisocabtagene maraleucel
PMID 42669548A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression.Journal of clinical and experimental hematopathology : JCEH2026name in abstract: lisocabtagene maraleucel
PMID 42875607Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study.International journal of clinical oncology2026cited by trial NCT04245839
PMID 42908725Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing after CD19 CAR T-cell therapy.Frontiers in medicine2026name in abstract: lisocabtagene maraleucel
PMID 42909844Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States.Advances in therapy2026cited by trial NCT03575351
PMID 39479862Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world.Haematologica2025cited by trial NCT03483103
PMID 39580347Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: Multicenter nursing/advanced practice provider perspectives.Seminars in oncology nursing2025name in title: lisocabtagene maraleucel
PMID 39657136Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.Blood advances2025name in title: lisocabtagene maraleucel
PMID 39938007Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.Blood2025name in abstract: lisocabtagene maraleucel
PMID 40025178Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.Bone marrow transplantation2025name in abstract: lisocabtagene maraleucel
PMID 40305658Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.Blood advances2025cited by trial NCT03483103
PMID 40589238Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.British journal of haematology2025name in abstract: liso-cel
PMID 40623279Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025cited by trial NCT03575351
PMID 40663365FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in title: lisocabtagene maraleucel
PMID 40708270Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma.Leukemia & lymphoma2025name in title: lisocabtagene maraleucel
PMID 40815804Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.Blood advances2025name in abstract: lisocabtagene maraleucel
PMID 41016810Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.Journal of clinical and experimental hematopathology : JCEH2025name in abstract: lisocabtagene maraleucel
PMID 41117994Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy.International journal of hematology2025name in abstract: lisocabtagene maraleucel
PMID 37646670Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.Haematologica2024cited by trial NCT03483103
PMID 37890149Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.Blood2024cited by trial NCT02631044
PMID 38072625Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024cited by trial NCT02631044
PMID 38324398FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research2024name in title: lisocabtagene maraleucel
PMID 38547003Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.Future oncology (London, England)2024cited by trial NCT03575351
PMID 38552193Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024name in abstract: lisocabtagene maraleucel
PMID 38802271Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.Journal for immunotherapy of cancer2024name in abstract: lisocabtagene maraleucel
PMID 38830991Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.Nature medicine2024cited by trial NCT04245839
PMID 38854403A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.Blood cell therapy2024name in abstract: lisocabtagene maraleucel
PMID 39347584OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.Blood advances2024cited by trial NCT03744676
PMID 36542826Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.Blood2023cited by trial NCT03575351
PMID 36575360CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.Bone marrow transplantation2023name in abstract: lisocabtagene maraleucel
PMID 36755418Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.Leukemia & lymphoma2023cited by trial NCT02631044
PMID 37295445Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.Lancet (London, England)2023cited by trial NCT03331198
PMID 37544410Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.Transplantation and cellular therapy2023cited by trial NCT03575351
PMID 37873752Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma.Medical sciences (Basel, Switzerland)2023name in abstract: lisocabtagene maraleucel
PMID 38022532Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.Frontiers in immunology2023cited by trial NCT04855253
PMID 34699592Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.Blood2022cited by trial NCT03331198
PMID 35156195In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.Clinical pharmacology and therapeutics2022cited by trial NCT02631044
PMID 35337365Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.Experimental hematology & oncology2022cited by trial NCT02631044
PMID 35610089Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications.Cytotherapy2022cited by trial NCT02631044
PMID 35619325Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Cancer medicine2022name in title: lisocabtagene maraleucel
PMID 35717989Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.Lancet (London, England)2022cited by trial NCT03575351
PMID 35839786Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.The Lancet. Oncology2022cited by trial NCT03483103
PMID 36149968Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.Blood advances2022name in title: lisocabtagene maraleucel
PMID 33288485Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.Clinical lymphoma, myeloma & leukemia2021cited by trial NCT03575351
PMID 33720336Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.Blood advances2021cited by trial NCT02631044
PMID 33904895Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.Blood advances2021cited by trial NCT02631044
PMID 33970454Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.Advances in therapy2021cited by trial NCT02631044
PMID 34125421Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.Clinical pharmacokinetics2021cited by trial NCT02631044
PMID 34310745Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.American journal of hematology2021cited by trial NCT02631044
PMID 34493319Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.Journal of hematology & oncology2021cited by trial NCT02631044
PMID 34515338Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.The Cochrane database of systematic reviews2021cited by trial NCT02631044
PMID 32888407Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet (London, England)2020cited by trial NCT02631044

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39410883Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.Expert opinion on drug safety2026name in abstract: lisocabtagene maraleucel
PMID 40373976Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed/Refractory Large B-Cell Lymphoma: A US Cost-Effectiveness Analysis.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 40968610Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study.Cancer research and treatment2026name in abstract: lisocabtagene maraleucel
PMID 41138816Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 41183747Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 41207679T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.European journal of haematology2026name in abstract: liso-cel
PMID 41235976CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting.Transplantation and cellular therapy2026name in title: lisocabtagene maraleucel
PMID 41317374Successful treatment of refractory DLBCL coexisting with SLE using Liso-cel, complicated by cytokine release syndrome.Rheumatology (Oxford, England)2026name in title: liso-cel
PMID 41345759Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review.PharmacoEconomics2026name in abstract: lisocabtagene maraleucel
PMID 41391508Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 41396346Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.PharmacoEconomics - open2026name in abstract: lisocabtagene maraleucel
PMID 41483380Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.International journal of hematology2026name in title: lisocabtagene maraleucel
PMID 41492445Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.Therapeutic advances in hematology2026name in abstract: lisocabtagene maraleucel
PMID 41504990Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan.International journal of clinical oncology2026name in title: lisocabtagene maraleucel
PMID 41529329Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma.Cytotherapy2026name in abstract: lisocabtagene maraleucel
PMID 41651792Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma.European journal of haematology2026name in title: lisocabtagene maraleucel
PMID 41698482Hypogammaglobulinemia at Leukapheresis Predicts Delayed Humoral Immune Reconstitution and Increased Risk of Infections After CD19 CAR-T for B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 41707107Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.Blood advances2026name in title: lisocabtagene maraleucel
PMID 41748023Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 41760136Lisocabtagene Maraleucel.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026name in title: lisocabtagene maraleucel
PMID 41762956Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy.Cytotherapy2026name in abstract: lisocabtagene maraleucel
PMID 41774434A new era for transplant-ineligible R/R LBCL patients: what's changing?Leukemia & lymphoma2026name in abstract: lisocabtagene maraleucel
PMID 41774517Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.Blood2026name in title: lisocabtagene maraleucel
PMID 41776243Lisocabtagene maraleucel has high efficacy in R/R MZL.Nature reviews. Clinical oncology2026name in title: lisocabtagene maraleucel
PMID 41777657Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice.Frontiers in oncology2026name in abstract: liso-cel
PMID 41825137NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: lisocabtagene maraleucel
PMID 41828393Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy.International journal of molecular sciences2026name in abstract: lisocabtagene maraleucel
PMID 41934060Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.Clinical lymphoma, myeloma & leukemia2026name in abstract: lisocabtagene maraleucel
PMID 41935576Neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 41964291Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.Transfusion2026name in abstract: liso-cel
PMID 41968224Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.International journal of clinical oncology2026name in abstract: lisocabtagene maraleucel
PMID 42018609Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.Blood advances2026name in abstract: lisocabtagene maraleucel
PMID 42050853Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.Leukemia & lymphoma2026name in title: lisocabtagene maraleucel
PMID 42052989Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).Leukemia & lymphoma2026name in abstract: lisocabtagene maraleucel
PMID 42081292A systematic analysis of the inherent dose uncertainty in autologous CAR T-cell products.Journal of biopharmaceutical statistics2026name in abstract: lisocabtagene maraleucel
PMID 42099680Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.HemaSphere2026name in abstract: lisocabtagene maraleucel
PMID 42138782Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma.Advances in therapy2026name in title: lisocabtagene maraleucel
PMID 42140929Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.Nature communications2026name in abstract: lisocabtagene maraleucel
PMID 42173255Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 42208766Delay differential equation modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies.Journal of pharmaceutical sciences2026name in title: liso-cel
PMID 42225561Re: 'Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma'.European journal of haematology2026name in title: lisocabtagene maraleucel
PMID 42265975Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.Cancer control : journal of the Moffitt Cancer Center2026name in abstract: lisocabtagene maraleucel
PMID 42279369Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience.Cancers2026name in abstract: lisocabtagene maraleucel
PMID 42305450Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis.Translational cancer research2026name in abstract: lisocabtagene maraleucel
PMID 42329247Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.Oncology (Williston Park, N.Y.)2026name in abstract: lisocabtagene maraleucel
PMID 42341926Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 42359427Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves.Cureus2026name in abstract: lisocabtagene maraleucel
PMID 42471153Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2026name in abstract: lisocabtagene maraleucel
PMID 42496442Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies.Hematology reports2026name in title: lisocabtagene maraleucel
PMID 42527721Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing.Current oncology reports2026name in abstract: lisocabtagene maraleucel
PMID 42534709Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T-Cell Therapy in TP53-Deleted CLL: A Case Report.EJHaem2026name in abstract: lisocabtagene maraleucel
PMID 42556536Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma.Transplantation and cellular therapy2026name in abstract: lisocabtagene maraleucel
PMID 42566728Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026name in abstract: lisocabtagene maraleucel
PMID 42567965Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.International journal of clinical oncology2026name in abstract: lisocabtagene maraleucel
PMID 42568509CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.Frontiers in immunology2026name in abstract: lisocabtagene maraleucel
PMID 42611409Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.Targeted oncology2026name in title: lisocabtagene maraleucel
PMID 42618274Late-onset Human Herpesvirus 6 Encephalitis with Secondary Hemophagocytic Lymphohistiocytosis after CAR T-cell Therapy.Internal medicine (Tokyo, Japan)2026name in abstract: lisocabtagene maraleucel
PMID 42625595Post-CAR T-cell thyroid dysfunction: destructive thyroiditis identified through thyroid function monitoring in a single-center cohort.Frontiers in oncology2026name in abstract: lisocabtagene maraleucel
PMID 42663433InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.European journal of haematology2026name in abstract: liso-cel
PMID 42671910Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma.Blood cancer discovery2026name in abstract: lisocabtagene maraleucel
PMID 42753811B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: lisocabtagene maraleucel
PMID 42800585Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation.Transplantation and cellular therapy2026name in title: lisocabtagene maraleucel
PMID 42807827Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma.Frontiers in oncology2026name in abstract: liso-cel
PMID 42821304Liso-cel delivers: is the debate over for 3L FL?Blood2026name in title: liso-cel
PMID 42831097Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System.Mayo Clinic proceedings. Innovations, quality & outcomes2026name in abstract: lisocabtagene maraleucel
PMID 42844744Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review.Journal of investigative medicine : the official publication of the American Federation for Clinical Research2026name in abstract: lisocabtagene maraleucel
PMID 42908664Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database.Frontiers in pharmacology2026name in abstract: Breyanzi
PMID 42950111Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.Leukemia & lymphoma2026name in abstract: lisocabtagene maraleucel
PMID 39418599Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.Blood advances2025name in abstract: lisocabtagene maraleucel
PMID 39462177Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.European journal of haematology2025name in abstract: lisocabtagene maraleucel
PMID 39546746A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.Blood advances2025name in title: lisocabtagene maraleucel
PMID 39666878Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.Blood cancer discovery2025name in abstract: lisocabtagene maraleucel
PMID 39779930T cell malignancies after CAR T cell therapy in the DESCAR-T registry.Nature medicine2025name in abstract: lisocabtagene maraleucel
PMID 39784146Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?Expert opinion on biological therapy2025name in abstract: liso-cel
PMID 39846935Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome.Cytotherapy2025name in abstract: lisocabtagene maraleucel
PMID 39883946Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.Blood advances2025name in abstract: lisocabtagene maraleucel
PMID 39893244Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.Bone marrow transplantation2025name in abstract: lisocabtagene maraleucel
PMID 39941798Improving Treatment Options for Patients with Double Refractory CLL.Cancers2025name in abstract: lisocabtagene maraleucel
PMID 39954961Impact of Real-World Clinical Factors on an Analysis of the Cost-Effectiveness of "Immediate CAR-T" Versus "Late CAR-T" as Second-Line Treatment for DLBCL Patients.Transplantation and cellular therapy2025name in abstract: lisocabtagene maraleucel
PMID 39958356Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.Frontiers in immunology2025name in abstract: lisocabtagene maraleucel
PMID 39966627Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.Nature reviews. Clinical oncology2025name in abstract: lisocabtagene maraleucel
PMID 40045329Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma.Experimental hematology & oncology2025name in title: lisocabtagene maraleucel
PMID 40066130Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.EJHaem2025name in title: lisocabtagene maraleucel
PMID 40079097Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up.Haematologica2025name in title: lisocabtagene maraleucel
PMID 40163049Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.Journal of medical economics2025name in abstract: lisocabtagene maraleucel
PMID 40209064Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia.Blood2025name in abstract: lisocabtagene maraleucel
PMID 40293655The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy.Current treatment options in oncology2025name in abstract: lisocabtagene maraleucel
PMID 40346502Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.BMC cancer2025name in abstract: liso-cel
PMID 40486643Navigating the risks and benefits of newly approved Lisocabtagene Maraleucel in mantle cell lymphoma treatment.Annals of medicine and surgery (2012)2025name in title: lisocabtagene maraleucel
PMID 40515863Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia.Discover oncology2025name in abstract: lisocabtagene maraleucel
PMID 40590814Yield-driven approach optimizes apheresis of CD19 chimeric antigen receptor-T cell therapy for patients with lymphoma.Cytotherapy2025name in abstract: lisocabtagene maraleucel
PMID 40658007Chimeric antigen receptor T-cell therapy in aggressive lymphomas.Current opinion in oncology2025name in abstract: lisocabtagene maraleucel
PMID 40675858Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia.Hematology/oncology clinics of North America2025name in abstract: lisocabtagene maraleucel
PMID 40689917Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase.Therapeutic innovation & regulatory science2025name in abstract: lisocabtagene maraleucel
PMID 40714188Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full Bayesian inference with a student's t-based M3 censoring approach for robust handling of outliers and BLQ data.Journal of pharmaceutical sciences2025name in abstract: liso-cel
PMID 40726603Low Occurrence of Ocular Adverse Events after CAR-T Cell Therapy.Ocular oncology and pathology2025name in abstract: lisocabtagene maraleucel
PMID 40729699How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor.Blood2025name in abstract: lisocabtagene maraleucel
PMID 40754556Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015-2024).Discover oncology2025name in abstract: liso-cel
PMID 40902836From R-CHOP to revolution: How CAR T-Cells, ADCs, and bispecific antibodies are transforming DLBCL treatment.Critical reviews in oncology/hematology2025name in abstract: lisocabtagene maraleucel
PMID 40985996A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection.Hematological oncology2025name in abstract: lisocabtagene maraleucel

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P30CA015704Cancer ImmunologyFRED HUTCHINSON CANCER CENTERBLEAKLEY, MARIE2025–2026name in abstract: lisocabtagene maraleucel
P30CA016672Stem Cell Biology & Cellular Therapy ProgramUNIVERSITY OF TX MD ANDERSON CAN CTRSHPALL, ELIZABETH J2019–2026name in abstract: lisocabtagene maraleucel
R01CA286488Enhancing CAR-T cell therapy for DLBCLWASHINGTON UNIVERSITYDIPERSIO, JOHN F.2026–2026name in abstract: liso-cel
R01CA309280Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumorsCHILDREN'S HOSP OF PHILADELPHIAMA, LEYUAN2026–2026name in abstract: Breyanzi
UG1HL108987Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1H. LEE MOFFITT CANCER CTR & RES INSTPIDALA, JOSEPH A2024–2026name in abstract: lisocabtagene maraleucel
UG1HL109137Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell TherapiesWASHINGTON UNIVERSITYPUSIC, ISKRA2024–2026name in abstract: lisocabtagene maraleucel

Notes

Lentiviral anti-CD19 4-1BB CAR with EGFRt, defined CD4:CD8 composition. Juno acquired by Celgene, then BMS.

How to cite

lisocabtagene maraleucel (AXP000016.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000016.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.